Clinical trial

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

NCT04118062

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BEHAVIORAL · Unmapped registry intervention Questionnaires Find medicine records · Find other trials using this name

BEHAVIORAL · Unmapped registry intervention Semi-structured individual interviews Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Focus Group Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention DELPHI Consensus Method Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-02-02

PhaseNA

Conditions

Metastatic Uveal Melanomaunresolved

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Luminal B Breast Cancerverified · MONDO: luminal B breast carcinoma

Pediatric Cancerverified · MONDO: childhood malignant neoplasm

Interventions

QuestionnairesBEHAVIORAL

Semi-structured individual interviewsBEHAVIORAL

Focus GroupOTHER

DELPHI Consensus MethodOTHER

Sponsors & collaborators

Institut Curielead sponsor

Mapped research locations

ParisFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04118062 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.